<- Go Home
Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Market Cap
N/A
Volume
N/A
Cash and Equivalents
$4.0M
EBITDA
-$21.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
N/A
52 Week Low
N/A
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$21.1M
Return on Equity
924.32%
Return on Assets
-115.96
Cash and Short Term Investments
$4.0M
Debt
$456.0K
Equity
$52.0K
Revenue
N/A
Unlevered FCF
-$10.0M
Sector
Biotechnology
Category
N/A